FNAM

Evolutionary Genomics, Inc. FNAM

Net profit

EBITDA

P/E Ratio

Capitalization

Performance

Periode FNAM CLABF ENZN TDSGF SRNE DOSEF SIGY REPCF LIFD HLYK
6M 0.00 % -99.98 % -50.24 % -12.96 % -54.55 % -90.43 % -37.82 % -95.00 % -26.32 % -12.22 %
YTD -75.00 % -99.98 % -76.56 % -42.05 % 25.00 % -63.27 % -45.71 % -90.00 % -42.86 % -12.22 %
1Y -75.00 % -99.99 % -80.82 % -37.25 % 42.86 % -63.27 % -45.71 % -90.00 % -42.86 % -32.19 %
3Y -99.97 % -100.00 % -83.45 % -80.78 % -86.51 % -77.07 % 584.00 % -98.05 % -87.27 % -73.67 %
5Y -99.98 % -100.00 % -82.94 % -83.90 % -98.73 % -92.63 % 17.93 % -99.41 % -93.07 % -86.26 %
10Y -99.99 % -100.00 % -95.06 % -83.90 % -98.94 % -92.63 % 17.93 % -99.95 % -62.67 % -95.49 %
From the beginning -100.00 % -100.00 % -96.94 % -83.90 % -98.84 % -92.63 % 17.93 % -99.94 % -92.53 % -95.49 %

Dividend

Enzon Pharmaceuticals, Inc.